These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 23873327)

  • 81. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
    Bhandari B; Subramanian L
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial.
    Arnold SV; Kosiborod M; Li Y; Jones PG; Yue P; Belardinelli L; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2014 Nov; 7(6):844-50. PubMed ID: 25249560
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study.
    Olympios C; Stafylas P; Dermitzakis A; Efthimiadis I; Gardikiotis A; Kakouros S; Lampropoulos S; Barbetseas J; Sourgounis A; On Behalf Of Ranger Investigators
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541898
    [No Abstract]   [Full Text] [Related]  

  • 84. Ranolazine: a novel agent that improves dysfunctional sodium channels.
    Pham DQ; Mehta M
    Int J Clin Pract; 2007 May; 61(5):864-72. PubMed ID: 17493093
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris.
    Rich MW; Crager M; McKay CR
    Am J Geriatr Cardiol; 2007; 16(4):216-21. PubMed ID: 17617747
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ranolazine: a new approach to management of patients with angina.
    Tafreshi MJ; Fisher E
    Ann Pharmacother; 2006 Apr; 40(4):689-93. PubMed ID: 16595572
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Inhibition of sodium-dependent calcium overload to treat myocardial ischemia.
    Conti CR
    Clin Cardiol; 2006 Apr; 29(4):141-3. PubMed ID: 16649721
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
    Pepine CJ; Wolff AA
    Am J Cardiol; 1999 Jul; 84(1):46-50. PubMed ID: 10404850
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Late sodium current inhibition as a new cardioprotective approach.
    Hale SL; Shryock JC; Belardinelli L; Sweeney M; Kloner RA
    J Mol Cell Cardiol; 2008 Jun; 44(6):954-967. PubMed ID: 18462746
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Does ranolazine have a place in the treatment of acute coronary syndromes?
    Newby LK; Peterson ED
    JAMA; 2007 Apr; 297(16):1823-5. PubMed ID: 17456825
    [No Abstract]   [Full Text] [Related]  

  • 92. Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy.
    Slavich M; Maranta F; Fumero A; Godino C; Giannini F; Oppizzi M; Colombo A; Fragasso G; Margonato A
    Am J Cardiol; 2016 May; 117(10):1558-1561. PubMed ID: 27055755
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study.
    Zweiker R; Aichinger J; Metzler B; Lang I; Wallner E; Delle-Karth G
    Wien Klin Wochenschr; 2019 Apr; 131(7-8):165-173. PubMed ID: 30963332
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Enhanced external counter pulsation in treatment of refractory angina pectoris: two year outcome and baseline factors associated with treatment failure.
    Erdling A; Bondesson S; Pettersson T; Edvinsson L
    BMC Cardiovasc Disord; 2008 Dec; 8():39. PubMed ID: 19094202
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Evolving treatment strategies for chronic refractory angina.
    Yang EH; Barsness GW
    Expert Opin Pharmacother; 2006 Feb; 7(3):259-66. PubMed ID: 16448320
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Myopathy during treatment with the antianginal drug ranolazine.
    Kassardjian CD; Tian X; Vladutiu G; Wong LJ; Milone M
    J Neurol Sci; 2014 Dec; 347(1-2):380-2. PubMed ID: 25466697
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [New agents for the therapy of angina pectoris].
    Meinertz T; Köster R
    Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
    Peters CH; Sokolov S; Rajamani S; Ruben PC
    Br J Pharmacol; 2013 Jun; 169(3):704-16. PubMed ID: 23472826
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Ranolazine as add-on therapy for patients with severe chronic angina.
    Pechlaner C; Wiedermann C
    JAMA; 2004 Apr; 291(16):1959; author reply 1959-60. PubMed ID: 15113811
    [No Abstract]   [Full Text] [Related]  

  • 100. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
    Timmis AD; Chaitman BR; Crager M
    Eur Heart J; 2006 Jan; 27(1):42-8. PubMed ID: 16176940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.